Clinical Trial

A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Study acronym: ECLAT
Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
Lack of accrual
Summary
The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL. This is the first time the combination of drugs is being tested.
Protocol Amendment History 5 changes
critical Trial status changed: Recruiting → Withdrawn 2026-04-08
notable Enrollment reduced: 27 -> 0 participants 2026-04-08
notable Trial sites reduced: 7 -> 0 locations 2026-04-08
notable Primary completion moved earlier: 2028-08 -> 2026-03-31 2026-04-08
minor Completion moved earlier: 2028-08 -> 2026-03-31 2026-04-08
Trial Details
NCT Number NCT07030699
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Genmab, Incyte Corporation
Conditions Lymphoma
Start Date 2025-08-13
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-07